Vlad Coric, Biohaven CEO (Jordan Sirek/Bloomberg via Getty Images)
Pfizer wagers $1.2B on Biohaven's lead migraine drug — and picks up a next-gen candidate — as marketing wars heat up
In the year and a half since Biohaven landed an FDA approval for Nurtec, the New Haven-based biotech has worked hard to overcome what …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
